NCT07665073Not yet recruitingPhase 4
Risperidone vs Cariprazine in Acute Mania
Risperidone vs Cariprazine in Acute Mania a Head to Head Comparison of Efficacy vs Tolerability
Source: ClinicalTrials.gov · Last updated 24 Jun 2026
Brief summary (registry, in English)
Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks. Primary outcome is change in YMRS total score from baseline to week 6.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 18 Jun 2026
- Start date
- Jun 2027
- Primary completion date
- Jun 2028
- Lead sponsor
- Pakistan Institute of Medical Sciences
- Diseases
- Bipolar disorder
- NCT number
- NCT07665073
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 50
- From Jun 2027 to the primary completion date, Jun 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with substance use Patients already taking antipsychotics Secondary mood disorder
Other
- \-
Who the study is looking for
- patients with bipolar mania Age 18-60 YMRS\>20 -
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.